JW (Cayman) Therapeutics Co. Ltd (JW THERAP-B) filed its Monthly Return with Hong Kong Exchanges and Clearing Limited for the period ended 30 April 2026, detailing modest equity changes driven by option activity.

Authorised Capital Stable • Authorised share capital remained unchanged at 5.00 billion ordinary shares with a par value of USD 0.00001 each, equivalent to total authorised capital of USD 50,000.

Issued Share Capital Movement • Issued shares (excluding treasury shares) increased by 256,183 to 416.73 million, a 0.06% expansion versus the previous month’s 416.47 million. • No treasury shares were held or transacted during the month, leaving total issued shares equal to shares in public hands. • The company confirms compliance with Hong Kong’s minimum 25% public-float requirement.

Drivers of Share Increase • All new shares stemmed from exercises under the Post-IPO Incentivization Scheme (grant date 11 April 2025, exercise price HKD 1.48). • Proceeds from these exercises amounted to USD 48,609.08.

Share-Based Incentive Activity • Option exercises: 256,183 options exercised as noted above. • Option lapses: 300,000 options (grant date 24 June 2022, exercise price HKD 8.94) expired unexercised. • New grants: 8.04 million options awarded on 20 April 2026 at an exercise price of HKD 2.52. • Aggregate outstanding options at month-end rose to approximately 21.07 million.

Other Equity Instruments • No warrants, convertible securities or other equity-linked instruments were issued or outstanding changes reported. • The 2019 Restricted Share Unit Scheme retains an unissued reserve of 1.20 million shares; none were granted or vested in April.

Regulatory Compliance • The board affirmed that all share issuances were duly authorised and complied with Hong Kong Listing Rules and relevant legal requirements.

The filing underscores JW THERAP-B’s limited but strategic equity dilution during April, driven solely by employee incentive exercises, while maintaining a robust public float and stable authorised capital.